ClinicalTrials.gg
RecruitingNCT07402213Updated Aug 3, 2026

Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

A Phase 3 interventional study of JYB1904 and Placebo+JYB1904 in Chronic Spontaneous Urticaria, sponsored by Jemincare. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Jemincare · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Chronic Urticaria with a site in China — 16 open to participants now, 20 under way, 5 of them phase 3. Chronic Urticaria · China.

Planned enrollment
8th of 30
240 · median 110
Started
2026
with 10 others
Phase 3
8 of 34
1 open now
Primary completion
2027-06
later than 14 of 19 live
Registered
24th of 34
by date
Lead sponsor
2 of 34
Jemincare

Among the 34 studies in Chronic Urticaria with a site in China, this one is the 8th largest by planned enrollment of the 30 interventional ones that give a count, is one of 11 that started in 2026, is one of 8 in phase 3, reaches primary completion later than 14 of the 19 other live ones, and was the 24th registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

16 of the 34 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Chronic Urticaria with a site in China, or all of them as a file.
02

Study summary

This Phase III Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.

Read the detailed description

This study is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of JYB1904 injection compared to placebo in patients with CSU inadequately controlled by second-generation H1 antihistamines.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • CSU
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participant must be ≥18 years old at the time of signing the .
  • Participants are diagnosed with CSU for ≥6 months before screening.
  • Participants suffer from itching and hives for at least 6 consecutive weeks at any time before screening.
  • UAS7 (range 0\~42) ≥16, ISS7 (range 0\~21) ≥8 during 7 days before randomization.
  • Participants treated with stable dose of second-generation H1 antihistamines (up to 4x approved dose) for at least 6 consecutive weeks before randomization, switching medications, or changing drug dosage or frequency is not allowed within 3 weeks before randomization.
  • Participants have ≥6 days record of UAS7 before randomization.

Exclusion criteria

Exclusion Criteria:

  • Participants who suffer from inducible urticaria with definite inducements, including urticaria factitia (dermatographism), cold contact, heat contact, solar, pressure, delayed pressure, aquagenic, cholinergic or contact urticaria, etc.
  • Participants who suffer from any other skin diseases with chronic itching, such as atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis, etc.
  • Participants who suffer from other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary urticaria or acquired/drug-induced urticaria.
  • Participants who are or hypersensitive to antihistamines or any of its component (such as fexofenadine, loratadine, desloratadine, cetirizine, levocetirizine, rupatadine, bilastine).
  • History of anaphylactic shock.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    JYB1904 Injection Group

    300 mg JYB1904 injection administered SC

    Drug: JYB1904

  • Placebo comparator
    Placebo Group

    Placebo and 300 mg JYB1904 injection administered SC

    Drug: Placebo+JYB1904

Interventions

  • 300 mg JYB1904 injection administered SC every 12 weeks (Q12W) from Day 1 to Week 48.

    Also known as: JYB1904 Injection

  • DrugPlacebo+JYB1904

    Placebo administered SC on D1 and W12; 300 mg JYB1904 injection administered SC every 12 weeks (Q12W) from W24 to W48.

    Also known as: Placebo+JYB1904 Injection

06

What researchers measure

Primary outcomes

  1. Urticaria Activity Score Over 7 Consecutive Days(UAS7)

    Change from baseline in UAS7 at W12. The UAS7 is a composite score derived from the ISS7 and the HSS7, i.e., the sum of ISS7 and HSS7, ranging from 0 to 42 points. UAS7 = 0 indicates complete resolution of urticaria.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Itch Severity Score Over 7 Consecutive Days(ISS7)

    Change from baseline in ISS7 at W12. The ISS7 is the sum of mean daily scores over the 7 days prior to the visit, ranging from 0 to 21 points. ISS7 = 0 indicates complete resolution of itch.

    Time frame: Up to 12 weeks

  2. Urticaria Activity Score Over 7 Consecutive Days(UAS7)

    Proportion of participants with UAS7=0 at W12

    Time frame: Up to 12 weeks

  3. Urticaria Activity Score Over 7 Consecutive Days(UAS7)

    Change from baseline in UAS7 at W24

    Time frame: Up to 24 weeks

  4. Urticaria Activity Score Over 7 Consecutive Days(UAS7)

    Proportion of participants with UAS7=0 at W24

    Time frame: Up to 24 weeks

  5. Itch Severity Score Over 7 Consecutive Days(ISS7)

    Change from baseline in ISS7 at W24

    Time frame: Up to 24 weeks

  6. Hive Severity Score Over 7 Consecutive Days (HSS7)

    Change from baseline in HSS7 at W12 and W24. The HSS7 is the sum of mean daily scores over the 7 days prior to the visit, ranging from 0 to 21 points. HSS7 = 0 indicates complete resolution of hives.

    Time frame: Up to 24 weeks

  7. Angioedema Activity Score Over 7 Consecutive Days(AAS7)

    Change from baseline in AAS7 at W12 and W24. The AAS7 is the sum of the daily scores over the 7 days prior to the visit, ranging from 0 to 105 points.AAS7 = 0 indicates no angioedema.

    Time frame: Up to 24 weeks

  8. Urticaria Activity Score Over 7 Consecutive Days(UAS7)

    Proportion of participants with UAS7≤ 6 at W12 and W24

    Time frame: Up to 24 weeks

  9. Dermatology Life Quality Index(DLQI)

    Change from baseline in DLQI at W12 and W24. The DLQI comprises 10 questions that assess the participant's skin symptoms and the impact of their dermatological condition on multiple life domains over the past 7 days. The total score ranges from 0 to 30. The higher the score, the worse the quality of life.

    Time frame: Up to 24 weeks

  10. Efficacy Assessment Scale

    Change from baseline in UAS7, ISS7, HSS7, AAS7 (AAS7 only in participants with baseline AAS7\>0) over time during the study

    Time frame: Through study completion, an average of 72 weeks

  11. Efficacy Assessment Scale

    Proportion of participants with UAS7=0, ISS7=0, HSS7=0, AAS7=0 (AAS7 only in participants with baseline AAS7\>0) over time during the study

    Time frame: Through study completion, an average of 72 weeks

  12. Urticaria Activity Score Over 7 Consecutive Days(UAS7)

    Proportion of participants with UAS7≤ 6 over time during the study

    Time frame: Through study completion, an average of 72 weeks

  13. Dermatology Life Quality Index(DLQI)

    Change from baseline in DLQI over time during the study

    Time frame: Through study completion, an average of 72 weeks

  14. Dermatology Life Quality Index(DLQI)

    Proportion of participants with DLQI=0/1 over time during the study

    Time frame: Through study completion, an average of 72 weeks

  15. Urticaria Activity Score Over 7 Consecutive Days(UAS7)

    Cumulative number of weeks with UAS7 ≤ 6 by W12 and W24

    Time frame: Up to 24 weeks

  16. Angioedema Activity Score Over 7 Consecutive Days(AAS7)

    Cumulative number of weeks with AAS7 = 0 by W12 and W24

    Time frame: Up to 24 weeks

  17. Rescue Therapy

    Proportion of participants requiring rescue therapy by W12 and W24

    Time frame: Up to 24 weeks

  18. Safety and tolerability

    Adverse events (AEs) and serious adverse events (SAEs), vital signs, physical examination, 12-lead electrocardiogram (ECG) and laboratory results

    Time frame: Through study completion, an average of 72 weeks

Other outcomes

  1. Pharmacokinetic (PK) profile of JYB1904 injection

    Serum concentration of JYB1904

    Time frame: Through study completion, an average of 72 weeks

  2. Pharmacodynamic (PD) profile of JYB1904 injection

    PD parameters: Changes in serum level of total and free IgE

    Time frame: Through study completion, an average of 72 weeks

  3. Immunogenicity of JYB1904 injection

    Immunogenicity parameters: Positive detection rate of anti-drug antibodies (ADA)/neutralizing ADA (Nab), ADA onset time, duration, and titer

    Time frame: Through study completion, an average of 72 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's planned 14 months is below that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 11, 2026
StartActual
Mar 9, 2026
Primary completionEst.
Jun 7, 2027
CompletionEst.
Jun 9, 2028
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07402213
Lead sponsor
Jemincare
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Mar 9, 2026
Primary completion
Jun 7, 2027 (estimated)
Completion
Jun 9, 2028 (estimated)
Last update
Aug 3, 2026

Study contacts

Mingming Tan
Contact
tanmingming@jeyoupharma.com
021-58306003
Jianzhong Zhang
principal investigator · Peking University People's Hospital
Cheng Zhou
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ozureprubart

Start the discussion